Escalada do preço das casas bate subidas do Leste europeu

[Ulisses Pereira]

Curioso o comentário rápido do analista das biotecnológicas do Realmoney:

Adam Feuerstein

"Amgen didn't miss"
1/22/04 04:22 PM ET

"Who missed, Amgen or the analysts? There's a strong argument for the latter.

When Amgen provided financial guidance on Dec. 15, it forecast 2003 adjusted EPS in the middle of its $1.85 to $1.95 range. Well, Amgen reported tonight 2003 adjusted EPS of $1.90 per share. You don't need a calculator to see Amgen hit it's number exactly as forecast. Seems to me that analysts failed to adjust their models after the Dec. 15 conference call ? I guess that's their prerogative, but is it fair to say Amgen missed when it actually didn't?

Not that this matter since CNBC, Reuters, Bloomberg, etc. are all reporting that Amgen missed."

(in www.realmoney.com)

[Visitante]

Los beneficios del cuarto trimestre de Amgen (AMGN) crecieron un 20% pero no cumplieron con los estimados del mercado. La mayor empresa biotecnológica registró una ganancia neta de 546,9 millones, ó 41 centavos por acción, frente a 456,4 millones, ó 34 centavos de un año atrás. Sus ventas escalaron un 333% a 2.350 millones. Excluyendo extraordinarios dijo haber ganado 615 millones, ó 46 centavos por acción, dos centavos por debajo de los 48 centavos por título previstos por el consenso de analistas.